Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Narine Sarvazyan

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Journal of Cardiovascular Pharmacology and Therapeutics|February 7, 2014
Thinking Outside the Heart: Use of Engineered Cardiac Tissue for the Treatment of Chronic Deep Venous InsufficiencyNarine Sarvazyan
Frontiers in Physiology|February 17, 2022
Building Valveless Impedance Pumps From Biological Components: Progress and ChallengesNarine Sarvazyan
Cardiovascular Toxicology|July 27, 2007
The anthracyclines: when good things go badGiorgio Minotti, Narine Sarvazyan
Cardiovascular Toxicology|January 8, 2008
Adhesion proteins, stem cells, and arrhythmogenesisNikki Gillum, Narine Sarvazyan
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|October 24, 2022
The essential role of arterial pulse in venous returnNarine M LeFevre, Narine Sarvazyan
Cancer Research|October 3, 2003
Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicityLuther Swift, Jane McHowat, Narine Sarvazyan
Advances in Physiology Education|February 19, 2005
"Non-trivial pursuit of physiology"Vazgen Zakaryan, Richard Bliss, Narine Sarvazyan
Cardiovascular Toxicology|March 23, 2004
Multiple injury approach and its use for toxicity studiesAra Arutunyan, Luther Swift, Narine Sarvazyan
Cardiovascular Toxicology|July 27, 2007
Anthracycline-induced phospholipase A2 inhibitionLuther Swift, Jane McHowat, Narine Sarvazyan
Scientific Reports|September 22, 2020
Key factors behind autofluorescence changes caused by ablation of cardiac tissueNarine Muselimyan, Huda Asfour, Narine Sarvazyan
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Journal of Cardiovascular Pharmacology and Therapeutics|February 7, 2014
Thinking Outside the Heart: Use of Engineered Cardiac Tissue for the Treatment of Chronic Deep Venous InsufficiencyNarine Sarvazyan
Frontiers in Physiology|February 17, 2022
Building Valveless Impedance Pumps From Biological Components: Progress and ChallengesNarine Sarvazyan
Cardiovascular Toxicology|July 27, 2007
The anthracyclines: when good things go badGiorgio Minotti, Narine Sarvazyan
Cardiovascular Toxicology|January 8, 2008
Adhesion proteins, stem cells, and arrhythmogenesisNikki Gillum, Narine Sarvazyan
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|October 24, 2022
The essential role of arterial pulse in venous returnNarine M LeFevre, Narine Sarvazyan
Cancer Research|October 3, 2003
Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicityLuther Swift, Jane McHowat, Narine Sarvazyan
Advances in Physiology Education|February 19, 2005
"Non-trivial pursuit of physiology"Vazgen Zakaryan, Richard Bliss, Narine Sarvazyan
Cardiovascular Toxicology|March 23, 2004
Multiple injury approach and its use for toxicity studiesAra Arutunyan, Luther Swift, Narine Sarvazyan
Cardiovascular Toxicology|July 27, 2007
Anthracycline-induced phospholipase A2 inhibitionLuther Swift, Jane McHowat, Narine Sarvazyan
Scientific Reports|September 22, 2020
Key factors behind autofluorescence changes caused by ablation of cardiac tissueNarine Muselimyan, Huda Asfour, Narine Sarvazyan
Pageof 5